Skip to main content
Premium Trial:

Request an Annual Quote

23andMe, Nightingale Health Collaborate to Offer Blood-Based Metabolomic Testing

NEW YORK – 23andMe announced on Friday a collaboration with metabolomics firm Nightingale Health to pilot that company's blood-based metabolomics panel in a cohort of 23andMe members.

Under the pilot program, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members free blood testing using Nightingale's Remote Health Check panel.

Financial and other terms of the agreement were not disclosed.

The Remote Health Check panel measures dozens of metabolomic markers including cholesterols, apolipoproteins, and fatty acids like omega-3.

23andMe currently offers its annual members blood testing options as well as tools like its HealthTracks feature, which incorporates customer lifestyle choice into lifetime disease-risk calculations. The company said that adding blood biomarkers could improve the accuracy of these predictions and identify what interventions could be most impactful to a customer's health.

“We are truly impressed with Nightingale Health’s capabilities in blood biomarker testing," Anne Wojcicki, CEO and cofounder of 23andMe, said in a statement. "Their work with public biobank projects and resulting publications have previewed the exciting potential for metabolomics in prediction. We believe this collaboration will ultimately help our customers lead longer, healthier lives."

"This collaboration enables a globally unique feature set for 23andMe’s consumer health services," Teemu Suna, CEO and founder of Nightingale Health, said in a statement. "Together, we can help customers track and improve their health with regular blood testing using Nightingale Health’s technology. This marks an important step in the execution of Nightingale Health’s strategy, as it announces an important partnership providing access to the consumer health market."